Logo image of HLVX

HILLEVAX INC (HLVX) Stock Fundamental Analysis

NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD

1.88  +0.03 (+1.62%)

After market: 1.88 0 (0%)

Fundamental Rating

3

HLVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While HLVX has a great health rating, there are worries on its profitability. HLVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HLVX had negative earnings in the past year.
In the past year HLVX has reported a negative cash flow from operations.
HLVX had negative earnings in each of the past 5 years.
In the past 5 years HLVX always reported negative operating cash flow.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

HLVX has a Return On Assets (-59.81%) which is in line with its industry peers.
HLVX has a Return On Equity (-70.90%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.81%
ROE -70.9%
ROIC N/A
ROA(3y)-54.2%
ROA(5y)-132.62%
ROE(3y)-67.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HLVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for HLVX has been increased compared to 1 year ago.
Compared to 5 years ago, HLVX has more shares outstanding
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

HLVX has an Altman-Z score of -2.65. This is a bad value and indicates that HLVX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.65, HLVX perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.65
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

HLVX has a Current Ratio of 25.34. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
HLVX's Current ratio of 25.34 is amongst the best of the industry. HLVX outperforms 96.05% of its industry peers.
HLVX has a Quick Ratio of 25.34. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
HLVX has a better Quick ratio (25.34) than 96.05% of its industry peers.
Industry RankSector Rank
Current Ratio 25.34
Quick Ratio 25.34
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

HLVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.85%, which is quite impressive.
EPS 1Y (TTM)34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HLVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.28%
EPS Next 2Y33.95%
EPS Next 3Y20.9%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HLVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HLVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as HLVX's earnings are expected to grow with 20.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.95%
EPS Next 3Y20.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HLVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLEVAX INC

NASDAQ:HLVX (6/18/2025, 8:00:01 PM)

After market: 1.88 0 (0%)

1.88

+0.03 (+1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)N/A N/A
Inst Owners47.95%
Inst Owner Change-1.61%
Ins Owners2.08%
Ins Owner Change-0.15%
Market Cap94.26M
Analysts45.71
Price Target2.04 (8.51%)
Short Float %5.83%
Short Ratio6.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.16%
Min EPS beat(2)-104.08%
Max EPS beat(2)67.77%
EPS beat(4)1
Avg EPS beat(4)-15.58%
Min EPS beat(4)-104.08%
Max EPS beat(4)67.77%
EPS beat(8)4
Avg EPS beat(8)-5.34%
EPS beat(12)7
Avg EPS beat(12)-4.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)69.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0
BVpS3.01
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.81%
ROE -70.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.2%
ROA(5y)-132.62%
ROE(3y)-67.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.34
Quick Ratio 25.34
Altman-Z -2.65
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.63%
EPS Next Y80.28%
EPS Next 2Y33.95%
EPS Next 3Y20.9%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.4%
OCF growth 3YN/A
OCF growth 5YN/A